Jci_page_head_homepage_01 Jci_page_head_homepage_02
Maria B. Grant, Michael E. Boulton, Alexander V. Ljubimov
Published in Volume 118, Issue 2
J Clin Invest. 2008; 118(2):467–470 doi:10.1172/JCI34643
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 2
Epo’s angiogenic effects.

Epo has direct effects on resident vasculature, and it mobilizes circulating CD34+ BM-derived populations to stimulate their contribution to vascular repair in both acute and chronic injury models. BM-derived EPCs circulate in the bloodstream and migrate to areas of ischemia, respond to hypoxia-regulated factors such as Epo, and participate in both physiological and pathological neovascularization. Epo stimulates EPC proliferation, adhesion, and differentiation to endothelium, as do other hypoxia-regulated factors such as VEGF, stromal cell–derived factor 1 (SDF-1), and insulin-like growth factor–binding protein 3 (IGFBP-3).